-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Axis mutation (axonal degeneration) is an unresolved pathological phenomenon common to a wide range of neurological disorders that can cause severe sensations, movement and cognitive symptoms.
Jeffrey Milbrandt and Dr. Aaron DiAntonio of Washington University School of Medicine in St. Louis, the co-founders of Disarm, found that SARM1 proteins are the central driver of axis mutations.
disarm's SARM1 inhibitor is designed to directly prevent the loss of axons.
SARM1 plays a key role in shaft mutations (Photo: Disarm's official website) Lilly paid $135 million in upfront payments under the terms of the agreement.
disarm equity holders may be eligible for additional milestone payments of up to $1,225 million if Lilly successfully develops and commercializes the new drugs resulting from the acquisition.
: s1. Orca Bio Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Orca-T. Retrieved October 14, 2020, from.